---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-019883"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:19:29.423141+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome announces $138.1M cash estimate, commences public offering; updates pipeline and AL102 acquisition

## Summary
- Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.
- Underwritten public offering of common stock commenced; proceeds intended to fund pipeline and operations.
- Signed asset purchase agreement with Ayala for AL102 (GSI) in desmoid tumors; expected close in late Q1 or early Q2 2024.
- Pipeline: IND filings for IM-1021 (ROR1 ADC), IM-4320 (anti-IL-38), and FAP RLT all targeted for Q1 2025.
- CEO Clay Siegall (former Seagen CEO) leads; management team includes former Morphimmune executives.

## SEC filing metadata
- accession: 0001104659-24-019883
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/0001104659-24-019883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924019883/tm245878d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-019883
- JSON: https://secwatch.observer/filing/0001104659-24-019883.json
- Plain text: https://secwatch.observer/filing/0001104659-24-019883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.